Amyloid "accumulators": The next generation of candidates for amyloid-targeted clinical trials?

Affiliations

¹ From the Department of Neurology (C.T.M.), Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia; and Inserm UMR-S U1237 (G.C.), Université de Caen-Normandie, GIP Cyceron, Caen, France. mcmillac@upenn.edu.
² From the Department of Neurology (C.T.M.), Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia; and Inserm UMR-S U1237 (G.C.), Université de Caen-Normandie, GIP Cyceron, Caen, France.

Editorial

Corey T McMillan et al. Neurology. 2018.

. 2018 Apr 24;90(17):759-760.

doi: 10.1212/WNL.0000000000005362. Epub 2018 Mar 23.

¹ From the Department of Neurology (C.T.M.), Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia; and Inserm UMR-S U1237 (G.C.), Université de Caen-Normandie, GIP Cyceron, Caen, France. mcmillac@upenn.edu.
² From the Department of Neurology (C.T.M.), Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia; and Inserm UMR-S U1237 (G.C.), Université de Caen-Normandie, GIP Cyceron, Caen, France.

No abstract available

Comment on

Memory decline accompanies subthreshold amyloid accumulation.
Landau SM, Horng A, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Landau SM, et al. Neurology. 2018 Apr 24;90(17):e1452-e1460. doi: 10.1212/WNL.0000000000005354. Epub 2018 Mar 23. Neurology. 2018. PMID: 29572282 Free PMC article.